study, where in ATF7IP::JAK2 mediated acute lymphoblastic leukemia (ALL), CHZ-868 is potent against the ruxolitinib resistant variants such as Y931C and L983F (45). This evidence concerns the gene ATF7IP and acute lymphoblastic leukemia.